Cargando…

Predictive and prognostic role of early apolipoprotein A‐I alteration in recurrent or metastatic nasopharyngeal carcinoma patients treated with anti‐PD‐1 therapy

BACKGROUND: The primary objective of this study was to evaluate the predictive and prognostic value of serum lipids in recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) patients received anti‐PD‐1 therapy. MATERIALS AND METHODS: Patients treated with anti‐PD‐1 therapy (monotherapy or combin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiao, Bi Jing, Sima, Xiao Xian, Chen, Gang, Gulizeba, Haimiti, Zhou, Ting, Huang, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501269/ https://www.ncbi.nlm.nih.gov/pubmed/37409613 http://dx.doi.org/10.1002/cam4.6321

Ejemplares similares

Nomogram for predicting the prognosis of metastatic colorectal cancer patients treated with anti-PD1 therapy based on serum lipids analysis
por: Xiao, Bijing, et al.
Publicado: (2023)

Sarcopenia defined by skeletal muscle mass index at the third lumbar vertebra is a prognostic factor for extensive-stage small cell lung cancer patients: a retrospective study
por: Wang, Kai, et al.
Publicado: (2022)

Serum apolipoprotein A-I is a novel prognostic indicator for non-metastatic nasopharyngeal carcinoma
por: Luo, Xiao-Lin, et al.
Publicado: (2015)

Anti-PD1 checkpoint inhibitor with or without chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma
por: Jin, Ting, et al.
Publicado: (2020)

Are PD-1 inhibitors effective for recurrent/metastatic nasopharyngeal carcinoma? Meta-analysis and systematic review
por: Yan, Le, et al.
Publicado: (2023)

Apolipoprotein A-I Is a Prognosticator of Nasopharyngeal Carcinoma in the Era of Intensity-modulated Radiotherapy
por: Chang, Hui, et al.
Publicado: (2018)

Prognostic value of the serum apolipoprotein B to apolipoprotein A-I ratio in metastatic colorectal cancer patients
por: Yang, Dong-Dong, et al.
Publicado: (2020)

Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma
por: Lin, Jing, et al.
Publicado: (2022)

Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study
por: Ding, Xi, et al.
Publicado: (2023)

Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)
por: Yang, Yunpeng, et al.
Publicado: (2021)

Apatinib in treating patients with recurrent or metastatic nasopharyngeal carcinoma who had failed prior platinum-based chemotherapy
por: Tao, Chang-Juan, et al.
Publicado: (2020)

Prognostic factors in metastatic nasopharyngeal carcinoma
por: Toumi, Nabil, et al.
Publicado: (2020)

Prognostic Significance of Tumor Volume in Locally Recurrent Nasopharyngeal Carcinoma Treated with Salvage Intensity-Modulated Radiotherapy
por: Xiao, WeiWei, et al.
Publicado: (2015)

Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma
por: Lim, Darren Wan-Teck, et al.
Publicado: (2023)

Efficacy and safety of PD-1 inhibitors in recurrent or metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens: a systematic review and meta-analysis
por: Luo, Jian, et al.
Publicado: (2023)

Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer
por: Pei, Zhengda, et al.
Publicado: (2023)

Adjunctive PD-1 inhibitor versus standard chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis
por: Polintan, Edgar Theodore, et al.
Publicado: (2022)

Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial
por: Yuan, Li, et al.
Publicado: (2023)

Prognostic Value of a Serum Panel of Inflammatory Factors in Non-Metastatic Nasopharyngeal Carcinoma Patients Undergoing Radical Radiotherapy with Adjuvant Chemotherapy
por: Liang, Ting, et al.
Publicado: (2022)

Validation of a prognostic scoring system for locally recurrent nasopharyngeal carcinoma treated by stereotactic radiosurgery
por: Chua, Daniel TT, et al.
Publicado: (2009)

Radiological, pathological and DNA remission in recurrent metastatic nasopharyngeal carcinoma
por: Chan, Stephen L, et al.
Publicado: (2006)

Gemcitabine improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma
por: Hong, Shaodong, et al.
Publicado: (2016)

PD-1 and PD-L1 expression in 132 recurrent nasopharyngeal carcinoma: the correlation with anemia and outcomes
por: Zhou, Yajuan, et al.
Publicado: (2017)

The Glasgow Prognostic Score Predicts Poor Survival in Cisplatin-Based Treated Patients with Metastatic Nasopharyngeal Carcinoma
por: Chen, Cui, et al.
Publicado: (2014)

The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis
por: Huang, Zi-Lu, et al.
Publicado: (2019)

Neoantigen landscape in metastatic nasopharyngeal carcinoma
por: Lin, Mei, et al.
Publicado: (2021)

Neutrophil to apolipoprotein A‐I ratio as an independent indicator of locally advanced nasopharyngeal carcinoma
por: Li, Jing, et al.
Publicado: (2021)

Cetuximab or nimotuzumab in combination with chemotherapy for treating recurrent/metastatic nasopharyngeal carcinoma: A meta‑analysis and systemic review
por: Ni, Xiaoling, et al.
Publicado: (2023)

Albumin-to-Alkaline Phosphatase Ratio: A Novel Prognostic Index of Overall Survival in Cisplatin-based Chemotherapy-treated Patients with Metastatic Nasopharyngeal Carcinoma
por: Nie, Man, et al.
Publicado: (2017)

Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)
por: Wang, Feng-Hua, et al.
Publicado: (2021)

Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review
por: Prawira, A, et al.
Publicado: (2017)

Capecitabine Monotherapy as Palliative Treatment for Patients with Recurrent/Metastatic Nasopharyngeal Cancer
por: Alshamsan, Bader, et al.
Publicado: (2022)

Clinical Characteristics and Prognostic Factors of Early and Late Recurrence After Definitive Radiotherapy for Nasopharyngeal Carcinoma
por: Li, Feng, et al.
Publicado: (2020)

Prognostic Factors and Survival in Patients Treated Surgically for Recurrent Metastatic Uterine Leiomyosarcoma
por: Hoang, Han L. T., et al.
Publicado: (2014)

An immune-related prognostic model predicts neoplasm-immunity interactions for metastatic nasopharyngeal carcinoma
por: Chen, Xiaochuan, et al.
Publicado: (2023)

Chemo-Immunotherapy Regimes for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis
por: Zhu, Youwen, et al.
Publicado: (2022)

Development of a prognostic model to identify the metastatic nasopharyngeal carcinoma patients who may benefit from chemotherapy combination PD-1 inhibitor
por: Liu, Guo-Ying, et al.
Publicado: (2023)

Identification of Apolipoprotein E as a Potential Diagnostic Biomarker of Nasopharyngeal Carcinoma
por: Xue, Ying, et al.
Publicado: (2020)

Prognostic nutritional index predicts prognosis in patients with metastatic nasopharyngeal carcinoma
por: Wei, Gan-Bao, et al.
Publicado: (2016)

Neutrophil–lymphocyte ratios in the prognostication of primary non-metastatic nasopharyngeal carcinoma()
por: Liew, Kong Yew, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5eh7ull24g1cbbhj8ipln02e5m